KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to -$390.0 million.

  • Teva Pharmaceutical Industries' Tax Provisions fell 149285.71% to -$390.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$180.0 million, marking a year-over-year decrease of 12666.67%. This contributed to the annual value of -$180.0 million for FY2025, which is 12662.72% down from last year.
  • According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' Tax Provisions is -$390.0 million, which was down 149285.71% from $214.0 million recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Tax Provisions' 5-year high stood at $630.0 million during Q2 2024, with a 5-year trough of -$900.0 million in Q2 2022.
  • Its 5-year average for Tax Provisions is $2.9 million, with a median of $34.5 million in 2023.
  • Its Tax Provisions has fluctuated over the past 5 years, first surged by 403750.0% in 2024, then crashed by 149285.71% in 2025.
  • Teva Pharmaceutical Industries' Tax Provisions (Quarter) stood at -$24.0 million in 2021, then skyrocketed by 720.83% to $149.0 million in 2022, then crashed by 72.48% to $41.0 million in 2023, then tumbled by 31.71% to $28.0 million in 2024, then tumbled by 1492.86% to -$390.0 million in 2025.
  • Its last three reported values are -$390.0 million in Q4 2025, $214.0 million for Q3 2025, and -$78.0 million during Q2 2025.